[go: up one dir, main page]

WO2008091798A3 - Optimized ca9 antibodies and methods of using the same - Google Patents

Optimized ca9 antibodies and methods of using the same Download PDF

Info

Publication number
WO2008091798A3
WO2008091798A3 PCT/US2008/051470 US2008051470W WO2008091798A3 WO 2008091798 A3 WO2008091798 A3 WO 2008091798A3 US 2008051470 W US2008051470 W US 2008051470W WO 2008091798 A3 WO2008091798 A3 WO 2008091798A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
methods
optimized
same
parent antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/051470
Other languages
French (fr)
Other versions
WO2008091798A2 (en
Inventor
Matthew J Bernett
Wei Dang
John R Desjarlais
Gregory Alan Lazar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xencor Inc
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Publication of WO2008091798A2 publication Critical patent/WO2008091798A2/en
Publication of WO2008091798A3 publication Critical patent/WO2008091798A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention describes antibodies that target CA9, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
PCT/US2008/051470 2007-01-22 2008-01-18 Optimized ca9 antibodies and methods of using the same Ceased WO2008091798A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88605807P 2007-01-22 2007-01-22
US60/886,058 2007-01-22

Publications (2)

Publication Number Publication Date
WO2008091798A2 WO2008091798A2 (en) 2008-07-31
WO2008091798A3 true WO2008091798A3 (en) 2008-10-02

Family

ID=39580082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/051470 Ceased WO2008091798A2 (en) 2007-01-22 2008-01-18 Optimized ca9 antibodies and methods of using the same

Country Status (1)

Country Link
WO (1) WO2008091798A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
EP1524995B1 (en) 2002-07-01 2011-12-21 Wilex AG Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
PT2708559T (en) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2011149999A2 (en) 2010-05-27 2011-12-01 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
MX365235B (en) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly.
TWI855488B (en) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 Fcγriib-specific fc region variant
WO2014030750A1 (en) 2012-08-24 2014-02-27 中外製薬株式会社 MOUSE FcγRII-SPECIFIC Fc ANTIBODY
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
WO2015035044A2 (en) * 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
MX2017005774A (en) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use.
SG11201706014PA (en) 2015-02-05 2017-08-30 Chugai Pharmaceutical Co Ltd Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2016199097A1 (en) 2015-06-10 2016-12-15 National Research Council Of Canada Carbonic anhydrase ix-specific antibodies and uses thereof
JP7141336B2 (en) 2015-12-25 2022-09-22 中外製薬株式会社 Anti-myostatin antibodies and methods of use
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
KR102538749B1 (en) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Composition for prophylaxis or treatment of il-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
MX2020002667A (en) 2017-09-08 2020-08-03 Maverick Therapeutics Inc Constrained conditionally activated binding proteins.
KR20200132938A (en) 2018-03-15 2020-11-25 추가이 세이야쿠 가부시키가이샤 Anti-dengue virus antibodies with cross-reactivity against Zika virus and methods of use
US11555071B2 (en) 2018-06-03 2023-01-17 Lamkap Bio Beta Ltd. Bispecific antibodies against CEACAM5 and CD47
CN120484127A (en) * 2019-03-05 2025-08-15 武田药品工业有限公司 Constrained conditionally active binding proteins
US20220331457A1 (en) * 2019-07-02 2022-10-20 Telix International Pty Ltd Antibodies against caix with reduced affinity for the neonatal fc receptor
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
EP4055055B1 (en) 2020-12-18 2023-11-22 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
CN113045665B (en) * 2021-03-22 2022-05-13 徐州医科大学 CAIX-CAR-T cell driven by HVEM (high-voltage alternating current) co-stimulation signal as well as preparation method and application of CAIX-CAR-T cell
WO2023242351A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ag Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062972A2 (en) * 2001-02-07 2002-08-15 Wilex Ag Hybridoma cell line g250 and its use for producing monoclonal antibodies
WO2004017923A2 (en) * 2002-08-23 2004-03-04 Chiron Corporation Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
WO2005056759A2 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062972A2 (en) * 2001-02-07 2002-08-15 Wilex Ag Hybridoma cell line g250 and its use for producing monoclonal antibodies
WO2004017923A2 (en) * 2002-08-23 2004-03-04 Chiron Corporation Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
WO2005056759A2 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
IVANOV S ET AL: "Expression of hypoxia-inducible cell-surfaces transmembrane carbonic ahydrases in human cancer", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 158, no. 3, 1 March 2001 (2001-03-01), pages 905 - 919, XP002967850, ISSN: 0002-9440 *
NATSUME ET AL: "Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 306, no. 1-2, 30 November 2005 (2005-11-30), pages 93 - 103, XP005197267, ISSN: 0022-1759 *
SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591 - 6604, XP002271092, ISSN: 0021-9258 *
SHIELDS ROBERT L ET AL: "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 277, no. 30, 26 July 2002 (2002-07-26), pages 26733 - 26740, XP002442140, ISSN: 0021-9258 *
WRIGHT A ET AL: "Effect of glycosylation on antibody function: implications for genetic engineering", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 15, no. 1, 1 January 1997 (1997-01-01), pages 26 - 32, XP004016809, ISSN: 0167-7799 *

Also Published As

Publication number Publication date
WO2008091798A2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
WO2008091798A3 (en) Optimized ca9 antibodies and methods of using the same
WO2008091954A3 (en) Optimized cd40 antibodies and methods of using the same
WO2008121160A3 (en) Optimized antibodies that target cd5
WO2008098115A3 (en) Optimized igf-1r antibodies and methods of using the same
WO2008022152A3 (en) Optimized antibodies that target cd19
WO2007044616A3 (en) Optimized anti-cd30 antibodies
WO2008036688A3 (en) Optimized antibodies that target hm1.24
WO2009026117A3 (en) Novel compounds
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
WO2005092925A3 (en) Immunoglobulin variants outside the fc region
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
WO2008094538A3 (en) Regulatory t cell epitopes, compositions and uses thereof
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
WO2007058823A3 (en) Anti-egfr antibodies
WO2006104989A3 (en) Altered antibody fc regions and uses thereof
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2009112245A9 (en) Antibody against the csf-1 r
WO2009070243A3 (en) Wise binding antibodies and epitopes
WO2011091078A3 (en) Antibody fc variants with enhanced complement activity
WO2008115504A3 (en) Nucleic acids encoding humanized immunoglobulin that binds a4b7 integrin
WO2008098917A3 (en) Novel antibodies against igf-ir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08727918

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08727918

Country of ref document: EP

Kind code of ref document: A2